These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1150 related articles for article (PubMed ID: 9435316)

  • 1. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-alpha and HSVtk: perspectives for the generation of cancer vaccines.
    Santodonato L; D'Agostino G; Santini SM; Carlei D; Musiani P; Modesti A; Signorelli P; Belardelli F; Ferrantini M
    Gene Ther; 1997 Nov; 4(11):1246-55. PubMed ID: 9425449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide.
    Moschella F; Valentini M; Aricò E; Macchia I; Sestili P; D'Urso MT; Alessandri C; Belardelli F; Proietti E
    Cancer Res; 2011 May; 71(10):3528-39. PubMed ID: 21444678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
    Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
    J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
    Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
    Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.
    Ferrantini M; Proietti E; Santodonato L; Gabriele L; Peretti M; Plavec I; Meyer F; Kaido T; Gresser I; Belardelli F
    Cancer Res; 1993 Mar; 53(5):1107-12. PubMed ID: 8439955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
    Parviz M; Chin CS; Graham LJ; Miller C; Lee C; George K; Bear HD
    Cancer Immunol Immunother; 2003 Dec; 52(12):739-50. PubMed ID: 12827306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases.
    Kaido TJ; Maury C; Gresser I
    Cancer Res; 1995 Dec; 55(24):6133-9. PubMed ID: 8521404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor.
    Mokyr MB; Place AT; Artwohl JE; Valli VE
    Cancer Immunol Immunother; 2006 Apr; 55(4):459-68. PubMed ID: 15965646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
    Song W; Levy R
    Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
    Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
    Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
    Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors.
    Tong Y; Song W; Crystal RG
    Cancer Res; 2001 Oct; 61(20):7530-5. PubMed ID: 11606390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.
    Gabriele L; Proietti E; Greco G; Venditti M; Gresser I; Schirrmacher V; Von Hoegen P; Testa U; Modesti A; Cianfriglia M
    Invasion Metastasis; 1993; 13(3):147-62. PubMed ID: 8112975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors.
    Ben-Hur H; Kossoy G; Zandbank J; Zusman I
    Int J Mol Med; 2002 Apr; 9(4):425-30. PubMed ID: 11891540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
    Berenson JR; Einstein AB; Fefer A
    J Immunol; 1975 Jul; 115(1):234-8. PubMed ID: 1080165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.